TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit.

@article{Pauken2014TIGITAC,
  title={TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit.},
  author={Kristen E. Pauken and Elaine Wherry},
  journal={Cancer cell},
  year={2014},
  volume={26 6},
  pages={785-787}
}
Combination therapies are becoming a focal point in cancer immunotherapy. In this issue of Cancer Cell, Johnston and colleagues identify the TIGIT/CD226 pathway, which provides significant interest for combination with PD-1 pathway blockade to improve anticancer CD8(+) T cell responses, because it acts by a novel mechanism to regulate CD8(+) T cell functions within the tumor microenvironment. 
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-3 of 3 references

J

S. Cancer Cell Previews Gilfillan, C. J. Chan, +6 authors M. Colonna
Exp. • 2008
View 3 Excerpts
Highly Influenced

Nat

J. C. Sun, L. L. Lanier
Rev. Immunol. 11, 645–657. Welch, M.J., Teijaro, J.R., Lewicki, H.A., Colonna, M., and Oldstone, M.B. (2012). Virology 429, 163–170. • 2011
View 2 Excerpts

Proc

S. D. Blackburn, H. Shin, G. J. Freeman, E. J. Wherry
Natl. Acad. Sci. USA 105, 15016–15021. Callahan, M.K., and Wolchok, J.D. (2013). J. Leukoc. Biol. 94, 41–53. • 2008
View 2 Excerpts

Similar Papers

Loading similar papers…